First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: Amphastar Pharmaceuticals: the story is balanced — FDA approval announcements for new ANDA filings and biosimilar candidates - particularly high-value products…
★ Analysts see FY2027 revenue reaching $788M — +5.6% growth in a single year.
What Moves the Stock
1FDA approval announcements for new ANDA filings and biosimilar candidates - particularly high-value products with limited competition
2Biosimilar launch progress and market share capture for Fylnetra (Neulasta biosimilar) and pipeline products
3Generic drug pricing trends - particularly for core hospital injectable portfolio where pricing erosion or stabilization impacts margins
4Manufacturing capacity expansion updates and facility inspection outcomes (FDA Form 483s or warning letters)
5Competitive dynamics on key products - new entrants or supply disruptions affecting market share
6Generic injectable pharmaceuticals (~60-65% of revenue) - hospital-focused products including critical care medications, anesthetics, and emergency drugs
7Respiratory products (~20-25% of revenue) - primarily albuterol inhalers and nebulizer solutions for asthma/COPD treatment
8Biosimilar products (~10-15% of revenue) - complex biologics including Neulasta biosimilar (Fylnetra) and pipeline candidates
value - The stock trades at attractive valuation multiples (7.9x EV/EBITDA, 1.8x P/S) relative to specialty pharma peers…
Rising interest rates have moderate negative impact through higher financing costs for working capital (long inventory cycles for sterile…
Watch on earnings: FDA Orange Book updates for new generic drug approvals and first-to-file exclusivity periods, Biosimilar market share data from IQVIA or Symphony Health tracking Fylnetra penetration versus reference Neulasta, Generic drug price indices (AAM Generic Drug Price Index) showing industry-wide pricing trends.
One Sentence Summary:
Amphastar Pharmaceuticals: the story is balanced — fda approval announcements for new anda filings and biosimilar candidates - particularly high-value products with limited competition.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.